Cardiovascular, Renal and Metabolism (CVRM)皇冠登录地址

永利皇冠app

永利皇冠app

Shared risk factors of CVRM diseases are still often not diagnosed or addressed, 1-4永利皇冠app


Up to 20 million 永利皇冠app

people die from CVRM diseases each year, making them the leading causes of death across the globe5,6

Up to 94% 永利皇冠app

of people with type-2 diabetes in the US have at least one other cardiovascular, renal or metabolic condition7

永利皇冠app

of patients with heart failure also have chronic kidney disease8

Up to 40%永利皇冠app

of patients hospitalised for heart failure have diabetes9


皇冠登录地址

皇冠登录地址


皇冠登录地址


Atacand, Atacand HCT, Atacand Plus皇冠登录地址

candesartan cilexetil

Brilinta/Brilique皇冠登录地址

ticagrelor

Bydureon皇冠登录地址

exenatide

Byetta皇冠登录地址

exenatide injection

Crestor皇冠登录地址

rosuvastatin

Farxiga/Forxiga皇冠登录地址

dapagliflozin

Komboglyze皇冠登录地址

saxagliptin and metformin HCl

Kombiglyze XR皇冠登录地址

saxagliptin and metformin XR

Lokelma皇冠登录地址

Sodium zirconium cyclosilicate

Onglyza皇冠登录地址

saxagliptin

Plendil, Modip, Splendil, Munobal, Flodil 皇冠登录地址

felodipine

Qtern皇冠登录地址

dapagliflozin and saxagliptin

Seloken ZOK, Toprol-XL, Betaloc ZOK皇冠登录地址

metoprolol succinate

Symlin皇冠登录地址

pramlintide acetate

Tenormin, Tenormine, Prenormine, Atenol 皇冠登录地址

atenolol

XIGDUO皇冠登录地址

dapagliflozin and metformin HCI

XIGDUO XR 皇冠登录地址

dapagliflozin and metformin HCI extended-release

Zestril皇冠登录地址

lisinopril dihydrate


皇冠登录地址


皇冠登录地址

皇冠登录地址

皇冠登录地址


We follow the science to develop innovative treatments and ultimately, modify or even halt the natural course of the disease and regenerate organs. We are agnostic to drug modality, we identify and validate novel targets based on genetics and human target validation and then apply the best modality to modulate the target. Together with key experts throughout the world we collaborate to accelerate our scientific progress, and to further define patient populations that may benefit from the novel cardio-renal-metabolic therapies we are developing.

Regina Fritsche-Danielson SVP, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D

New modalities永利皇冠app


New technologies永利皇冠app


New biology永利皇冠app


Phase III/LCM Projects: refers to assets that are pivotal in Phase II/III, or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets (removed when launched in all applicable major markets).

 

永利皇冠app

Phase I

皇冠登录地址

  • AZD2373 nephropathy
  • AZD2693 NASH
  • AZD6615 CV disease
  • AZD8233 CV disease
  • AZD9977 CV disease
  • MEDI6570 cardiovascular disease
  • MEDI7219 type-2 diabetes

Phase II

皇冠登录地址

  • AZD4831 heart failure with a preserved ejection fraction
  • AZD5718 coronary artery disease
  • AZD8601 cardiovascular disease
  • cotadutide type-2 diabetes, obesity and NASH
  • MEDI3506 diabetic kidney disease
  • MEDI5884 cardiovascular disease
  • MEDI6012 cardiovascular disease
  • verinurad chronic kidney disease

Phase III

皇冠登录地址

  • Epanova severe hypertriglyceridaemia
  • Lokelma hyperkalaemia
  • roxadustat OLYMPUS ROCKIES anaemia in chronic kidney disease/end-stage renal disease

LCM Projects

皇冠登录地址

  • Brilinta/Brilique THALES acute ischaemic stroke or transient ischaemic attack
  • Brilinta/Brilique HESTIA prevention of vaso-occlusive crises in paediatric patients with sickle cell disease
  • Brilinta/Brilique THEMIS cardiovascular outcomes trial in patients with coronary artery disease and type-2 diabetes without a previous history of myocardial infarction or stroke
  • Bydureon BCise (autoinjector) type-2 diabetes
  • Farxiga/Forxiga Dapa-CKD renal outcomes and cardiovascular mortality in patients with chronic kidney disease
  • Farxiga/Forxiga Dapa-HF worsening heart failure or cardiovascular death in patients with chronic heart failure (HFrEF)
  • Farxiga/Forxiga DECLARE- TIMI 58 cardiovascular outcomes trial in patients with type-2 diabetes
  • Farxiga/Forxiga DELIVER worsening HF or CV death in patients with chronic heart failure (HFpEF)
  • Farxiga/Forxiga DEPICT type-1 diabetes
  • Farxiga/Forxiga DETERMINE-Preserved heart failure with preserved ejection fraction (HFpEF)
  • Farxiga/Forxiga DETERMINE-Reduced heart failure with reduced ejection fraction (HFrEF)
  • Qternmet XR/Qtrilmet (saxagliptin/dapagliflozin metformin) type-2 diabetes
  • roxadustat anaemia in myelodysplastic syndrome
  • roxadustat chemotherapy induced anaemia
  • Xigduo XR/Xigduo type-2 diabetes


皇冠登录地址


皇冠登录地址


皇冠登录地址

 


皇冠登录地址


References

1.      Bjornstad et al. Curr Opin Endocrinol Diabetes Obes. 2014 August ; 21(4): 279–286. doi:10.1097/MED.0000000000000074.

2.      Narisa Futrakul, Ankanee Chanakul, Prasit Futrakul & Tawatchai Deekajorndech (2015) Early stage of vascular disease and diabetic kidney disease: an underrecognized entity, Renal Failure, 37:8, 1243-1246, DOI: 10.3109/0886022X.2015.1073054

3.      Liviu Segall, Ionut Nistor, and Adrian Covic, “Heart Failure in Patients with Chronic Kidney Disease: A Systematic Integrative Review,” BioMed Research International, vol. 2014, Article ID 937398, 21 pages, 2014. https://doi.org/10.1155/2014/937398.

4.      Edelman Intelligence Relevance and barriers amongst EU specialists Survey 2018. Document ID: Z2-0050 | Date of preparation: August 2018 | Date of expiry: July 2020

5.      Wang H et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: A systematic analysis for the Global Burden of Disease Study 2015. The Lancet 2016; 388(10053):1459–544.

6.      World Health Organization. (2019). World Heart Day. [online] Available at: https://www.who.int/cardiovascular_diseases/world-heart-day/en/ [Accessed 31 Jul. 2019].

7.      Arnold SV et al. Burden of cardio-renal-metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry. Diabetes Obes Metab 2018; 20(8):2000–3.

8.      Shiba N, Shimokawa H. Chronic kidney disease and heart failure--Bidirectional close link and common therapeutic goal. J Cardiol 2011; 57(1):8–17.

9.      ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal (2013) 34, 3035–3087 doi:10.1093/eurheartj/eht108

10.   JernBerg T et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J 2015; 36:1163-1170.

11.   National Institute of Diabetes and Digestive and Kidney Diseases. Kidney Disease Statistics for the United States: December 2016. National Institutes of Health [cited 2018 Aug 28]. Available from: URL: https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease.

12.   AstraZeneca data on file. Programme screening and treatment & Total programme KPIs. June 2019.

13.   R.L. Sacco et al. The Heart of 25 by 25: Achieving the Goal of Reducing Global and Regional Premature Deaths from Cardiovascular Diseases and Stroke. Circulation 2016; 133:e674-e690. Available at:  https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000000395 Last accessed July 2019.

 


Veeva ID: Z4-23524

Date of next review: July 2021